Answers are grounded in this paper and cite their sources.
Background Second or subsequent relapses of Wilms tumour (WT) are rarely reported. We assessed the characteristics, treatments, and outcome of such patients through a retrospective international cohort study of patients treated according to recent SIOP-RTSG protocols. Methods Patients with a second or subsequent relapse enrolled in SIOP WT 2001 and the UK-IMPORT study, and registered in the SIOP-RTSG database between 2001 and 2021 were included. Risk groups were defined per the SIOP-RTSG-2016 UMBRELLA protocol (AA-BB (second relapse after initial standard risk (AA) relapse), BB-CC (initial high risk (BB) relapse), and CC-CC (initial very high risk (CC) relapse). Five-year event-free survival (EFS) and overall survival (OS) rates were estimated using Kaplan-Meier and competing risk methods; survival between relapse risk groups was compared with log-rank testing. Findings Among 572 patients with first relapse, 114 (20%) patients experienced a subsequent relapse. The estimated 5-year EFS and OS after second relapse were 17.7% (95% Confidence Interval (CI): 11.1–28.0%) and 22.4% (95% CI: 15.3–32.9%). In group AA-BB (n = 39) 5-year EFS and OS were 39.0% (95% CI: 25.0–60.7%) and 41.0% (95% CI: 26.8–62.8%). In group BB-CC (n = 32), 5-year EFS was 14.8% (95% CI: 6.05–36.3%) and 5-year OS was 21.9% (95% CI: 10.9–44.0%). All CC-CC patients (n = 35) either died within 3 years of the second relapse or lacked adequate follow-up. Group AA-BB had predominantly been treated with ICE/CyCE regimens, and group BB-CC patients mainly with VIT/TOTEM regimens. Conclusion A second relapse WT remains curable in a proportion of AA-BB patients. In contrast, survival rates for BB-CC patients are minimal and dismal for CC-CC patients, who should be allocated to a relevant early-phase trial if feasible.
No takes yet. Share an insight, caveat, or question.
Groenendijk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: